Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Clinical Trial ID NCT01072175

PubWeight™ 66.16‹?›

🔗 Visit the page for NCT01072175

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012 13.48
2 Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012 6.21
3 Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012 3.10
4 Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2012 2.45
5 Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One 2012 2.40
6 BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 2011 2.10
7 Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol 2015 2.00
8 Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012 1.96
9 Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol 2011 1.59
10 Targeting BRAF for patients with melanoma. Br J Cancer 2010 1.56
11 Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 2014 1.55
12 Melanoma: new insights and new therapies. J Invest Dermatol 2012 1.54
13 Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 2013 1.36
14 Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol 2016 1.27
15 Beyond BRAF: where next for melanoma therapy? Br J Cancer 2014 1.26
16 Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 2012 1.25
17 The MAPK pathway across different malignancies: a new perspective. Cancer 2014 1.22
18 Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies. Cancer J 2012 1.18
19 Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res 2013 1.13
20 Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 2015 1.11
21 Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targets. Sci Signal 2013 1.08
22 Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther 2013 1.07
23 KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One 2012 0.96
24 Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS One 2014 0.95
25 Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One 2014 0.93
26 Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther 2014 0.92
27 Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. Dermatol Res Pract 2011 0.91
28 Adaptive resistance to RAF inhibitors in melanoma. Pigment Cell Melanoma Res 2014 0.91
29 Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy. Oncogene 2015 0.90
30 Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Front Oncol 2013 0.89
31 The current state of targeted therapy in melanoma: this time it's personal. Semin Oncol 2012 0.86
32 Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. Mol Cancer 2012 0.82
33 Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies. Front Pharmacol 2011 0.81
34 Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology 2016 0.81
35 Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol 2014 0.81
36 Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget 2015 0.81
37 Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol 2016 0.80
38 Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma. Expert Opin Investig Drugs 2011 0.78
39 Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma. Melanoma Res 2015 0.78
40 Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg 2012 0.78
41 Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy. Clin Cancer Res 2015 0.76
42 Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nat Med 2016 0.76
Next 100